Data as of Mar 13
| -0.26 / -3.33%|
NeoStem, Inc. is a biopharmaceutical company. It develops and builds core capabilities in cell therapy to capitalize on the paradigm shift. The company anticipates that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. The company operates through three segments: Cell Therapy-United States, Regenerative Medicine-China and Pharmaceutical Manufacturing-China. The Cell Therapy-United States segment is focused on the development of proprietary cellular therapies in cardiovascular disease, immunology and regenerative medicine and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science. Within this segment, the company provides adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use. The Regenerative Medicine-China segment initiatives including: constructing a stem cell research and development laboratory and processing and manufacturing facility in Beijing, establishing relationships with hospitals to provide stem cell-based therapies, and obtaining product licenses covering certain adult stem cell therapeutics focused on regenerative medicine. The Pharmaceutical Manufacturing-China provides clinical development efforts on products under development. The company was founded in September 1980 and is headquartered in New York, NY.
|Robin L. Smith||Chairman, CEO & Head-Investor Relations|
|Robert Dickey||Chief Financial Officer|
|Douglas W. Losordo||Chief Medical Officer|
|Robert A. Preti||Chief Scientific Officer|
|Timothy C. Fong||Vice President-Technology & Product Development|